Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

AZ, Daiichi Sankyo strengthen case for HER2 candidate

AZ, Daiichi Sankyo strengthen case for HER2 candidate Will rival Roche's HER2 franchise if approved. AstraZeneca’s big bet on a Daiichi Sankyo-developed HER2-targeting antibody-drug conjugate looks like its about to pay off, after delivering ... AZ and Daiichi Sankyo are looking at a possible approval for

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo

Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo US-based biotech is arguing the legal action is improper. Seattle Genetics has asked a court to dismiss a lawsuit brought a few weeks ago by Japan’s Daiichi Sankyo centring ... The two companies previously collaborated on ADC drug development between

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201 Daiichi said today that Seattle Genetics is “claiming certain intellectual property rights related to Daiichi Sankyo’s ADC products”, a stance which it insists is “without merit”. ... The original agreement between the companies cover ADCs

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata Meanwhile, Daiichi Sankyo has said it will concentrate on first-line use of quizartinib after being turned down by regulators in Europe and the US, and says it recently completed enrolment ... There are differences between the two drugs, as quizartinib

Seattle Genetics preps filing next year for oral HER2 drug

Seattle Genetics preps filing next year for oral HER2 drug Competition in the HER2 category is heating up though, with a new antibody-drug conjugate from Daiichi Sankyo and AstraZeneca –  trastuzumab deruxtecan – angling for approval in the US in the second

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics